OR WAIT null SECS
January 09, 2020
The new business unit, as well as a new leadership team formed by AbbVie, will be effective upon closing of the acquisition in the first quarter of 2020.
Under the agreement, Almirall will leverage WuXi Biologics’ proprietary WuXiBody platform to develop bispecific antibodies for dermatological diseases.
Phillips-Medisize has announced that it is expanding its current Global Innovation and Development (GID) site in Struer, Denmark, to include a dedicated manufacturing development and clinical build unit.
Privately owned global pharmaceutical company, Galen, has announced the completion of its acquisition of a boutique healthcare company, POA Pharma.
January 08, 2020
The joint venture will develop next-generation cell and gene therapies incorporating Affimer proteins.
Roche will apply ProBioGen’s proprietary GlymaxX technology to boost the antibody-dependent cellular cytotoxicity activity of antibodies.
PhoreMost, a biopharma company based in the United Kingdom, and Boehringer Ingelheim have entered into a multi-project drug discovery collaboration agreement, it was revealed.
January 07, 2020
The companies plan to combine their preclinical candidates to develop small-molecule inhibitors against multiple drug targets.
January 03, 2020
Through the acquisition, Johnson & Johnson will gain access to Taris’ lead clinical-stage product, TAR-200.
January 02, 2020
The promise of new therapies is tempered by the need for affordability, safety, and ethics.